Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ipsen SA
Despite the impact of the war in Ukraine and spiralling costs, as well as lower COVID-19-based revenues, the German group is forecasting a healthy financial performance for full-year 2022.
Still working to refile its NASH fibrosis NDA 22 months after an FDA complete response letter, Intercept gets $405m up front for its ex-US business, including commercial rights to Ocaliva in PBC.
Department of Defense awards series of contracts to meet Biden administration’s pledge to supply a billion at-home COVID-19 rapid tests.
First-in-class active-site polymerase inhibitor yields Phase Ib/IIa data showing suppression of HBV DNA. It also demonstrated a good safety profile with normalization of liver enzymes.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Clementia Pharmaceuticals, Inc.
- Ipsen Bioscience, Inc.
- Tercica, Inc.
- Syntaxin Ltd.
- OctreoPharm Sciences GmbH
- Octagen Corporation